Romiplostim for chronic ITP in children
Part of Blood & lymphatic clinical trials.
This trial tests whether a weekly injection of romiplostim can safely raise platelet counts in children with chronic immune thrombocytopenia (ITP) that has not improved with standard treatments. If effective, it may reduce bleeding risk and help children avoid more severe complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 1 and 18 years old.
- Child has chronic immune thrombocytopenia (ITP) — a long-term condition where the immune system destroys platelets.
- Child's first-line treatments (like steroids, IVIG, or eltrombopag) have not worked or caused too many side effects.
- Child's platelet count is below 30,000, or they are bleeding or at risk of bleeding with a count below 50,000.
- Child's ITP is not caused by another condition like HIV, hepatitis C, lupus, or a congenital (born with) problem.
- Parent or guardian must give written permission for the child to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
Hear when a new Romiplostim N01 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.